Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. We develop innovative endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA) allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives.
Our product portfolio contains three different endovascular platforms: AFX, Nellix and Ovation. The AFX® Endovascular AAA System is a technology that is delivering success across Europe and in US. The Nellix EVAS System, a novel aneurysm sealing system, is a highly differentiated technology platform that is designed to uniquely and completely fill and seal the aortic aneurysm sac as well as to treat the widest range of anatomies. It is on the market in several European countries and for investigational use in the U.S. Since February 2016, after the acquisition of Trivascular, our portfolio is completed with the Ovation product that combines a very low profile and a sealing technology designed to preserve patient from neck dilatation.
Endologix is the only company fully and exclusively dedicated to AAA with a three product platform to provide power of choice to physicians and adapt to each patient specificities.
At Endologix you will work in a fast paced environment with short decision making. We have an open atmosphere with strong collaboration between the different teams. There’s a huge commitment towards our customers and patients.